NCT04609566 2026-03-16Brentuximab Vedotin With Pembrolizumab in Metastatic Solid TumorsSeagen Inc.Phase 2 Completed161 enrolled
NCT04254107 2025-02-10A Safety Study of SEA-TGT (SGN-TGT) in Advanced CancerSeagen Inc.Phase 1 Terminated133 enrolled
NCT01196208 2020-09-21A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001Seagen Inc.No longer available
NCT00099255 2014-12-18Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell LymphomaSeagen Inc.Phase 2 Completed40 enrolled
NCT00051597 2011-10-12A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic MalignanciesSeagen Inc.Phase 1/2 Completed70 enrolled